Hudson Bay Capital Management LP Has $4.55 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Hudson Bay Capital Management LP grew its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 87.5% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 225,000 shares of the company’s stock after buying an additional 105,000 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $4,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Cromwell Holdings LLC boosted its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after acquiring an additional 629 shares during the period. Advisors Asset Management Inc. acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth about $41,000. Rothschild Investment LLC boosted its holdings in Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after purchasing an additional 1,348 shares during the period. JFS Wealth Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after purchasing an additional 2,000 shares during the period. Finally, LRI Investments LLC grew its position in shares of Teva Pharmaceutical Industries by 246.0% during the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analysts remain constructive: a blended analyst target around $37.67 and multiple recent upgrades/target raises suggest upside vs. the current share price, supporting positive sentiment among buy-side and brokers. Brokerages Set Teva Price Target at $37.67
• Positive Sentiment: Teva published its Q1 2026 Aide Memoire on the investor site — this consolidates prior public disclosures and reduces surprise risk ahead of Q1 results, which can limit downside from unexpected disclosures. Teva Releases Q1 2026 Aide Memoire
• Neutral Sentiment: Teva set a firm date for Q1 2026 results: press release on April 29 at 7:00 a.m. ET followed by a conference call/webcast at 8:00 a.m. ET — gives investors a clear roadmap to reprice the stock on confirmed quarterly metrics and management commentary. Teva to Host Q1 2026 Conference Call
• Negative Sentiment: Insider selling: Mark Sabag sold 62,102 shares on March 17 at an average $30.14 (≈$1.87M), trimming his stake by ~21.6% — significant insider sales can hurt near-term sentiment even if they are for personal/liquidity reasons. Insider Sale Disclosure — Mark Sabag

Insider Buying and Selling

In related news, EVP Richard Daniell sold 17,295 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the sale, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This represents a 16.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Richard D. Francis sold 442,935 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total value of $14,333,376.60. Following the completion of the sale, the chief executive officer directly owned 642,099 shares in the company, valued at $20,778,323.64. This trade represents a 40.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $28.72 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The company has a market cap of $33.02 billion, a PE ratio of 23.93, a price-to-earnings-growth ratio of 9.62 and a beta of 0.72. The company has a 50 day moving average of $32.66 and a 200-day moving average of $27.07. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the firm posted $0.71 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Finally, Bank of America increased their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.